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Bronchioalveolar carcinoma of the lung represents increasingly
recognized clinical entity with relatively high probability of re-
sponse to epidermal growth factor receptor tyrosine kinase inhibi-
tors. Patients who respond to these agents eventually develop resis-
tance. In this case report, we describe a patient who relapsed after
gefitinib treatment and achieved unusual response to vinflunine
single-agent chemotherapy, despite earlier progression to a combi-
nation of another vinca alkaloid and cisplatin. Molecular character-
ization of the primary tumor before any treatment is provided, and
mechanisms of resistance to epidermal growth factor receptor ty-
rosine kinase inhibitors are briefly discussed.
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(J Thorac Oncol. 2007;2: 91–92)
A 36-year-old never-smoking woman with unremarkablemedical history was diagnosed with a clinical stage IB
adenocarcinoma of the left lower lobe and referred to a
thoracic surgeon at the Medical University of Gdansk. At
surgery, limited metastatic spread to the pleura was found,
and the patient underwent left lower lobectomy with pari-
etal pleurectomy and mediastinal lymph node dissection.
Her postoperative course was uneventful, and the final
pathologic diagnosis was pT4N1M0 bronchioalveolar car-
cinoma (Figure 1A). The tumor showed marked epidermal
growth factor receptor (EGFR) protein expression by im-
munohistochemistry, EGFR gene amplification, and high
HER2 gene copy number by fluorescence in situ hybrid-
ization, and EGFR exon 19 E746_A750 deletion by bidi-
rectional sequencing (Fig. 1B–E). After 1 year of close
follow-up without any treatment, chest computed tomog-
raphy showed progression in the pleura, and the patient
received chemotherapy including cisplatin and vinorel-
bine. During the fifth cycle of chemotherapy, clinical and
radiographic progression in the pleura and the liver oc-
curred, and she received gefitinib 250 mg/day with almost
a complete response lasting for 17 months. Upon progres-
sion in the pleura and liver, patient received chemotherapy
with vinflunine on a clinical protocol. A significant radio-
graphic response was achieved at all sites of the disease,
confirmed by subsequent computed tomography examina-
tions. The response lasted 6 months, and then the patient
progressed. Subsequently, she received consecutively do-
cetaxel and oral etoposide with no response to either agent,
followed by palliative radiotherapy to the metastatic le-
sions in the left supraclavicular region, bones, and brain.
She died more than 4 years after the onset of advanced
bronchioalveolar carcinoma. Unfortunately, no tumor tis-
sue was available for analysis after the relapse to gefitinib.
DISCUSSION
Our patient had a typical clinical (female gender,
never-smoking history, and bronchioalveolar carcinoma
histology) and molecular (EGFR exon 19 deletion, high
EGFR and HER2 gene copy numbers, and high EGFR
protein level) features predicting a high-response proba-
bility and survival benefit to EGFR tyrosine kinase inhib-
itors (TKIs) in lung cancer. After relapse to gefitinib, she
was treated with a novel single-agent vinca alkaloid and
responded for 6 months, despite earlier progression to a
combination of another vinca alkaloid and cisplatin, indi-
cating the reversal of chemorefractory to chemosensitive
phenotype of the tumor. The response rate to the second-
line therapy in non-small cell lung cancer is typically less
than 10%, and the median time to progression is 2 to 3
months.1 Current treatment options for patients relapsing
after EGFR TKIs include chemotherapy or best supportive
care, depending mainly on the previous treatment and
performance status. Our case report indicates that a rela-
*Department of Medical Oncology, University of Colorado Cancer Center,
Aurora, CO; and Departments of †Oncology and Radiotherapy, ‡Biology
and Genetics, and §Thoracic Surgery, Medical University of Gdansk,
Gdansk, Poland.
Address for correspondence: Dr. Rafal Dziadziuszko, Department of Medical
Oncology, University of Colorado Cancer Center, P.O. Box 6511, Mail
Stop 8117, Aurora, CO 80045. E-mail: Rafal.Dziadziuszko@UCHSC.edu
Copyright © 2007 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/07/0201-0091
Journal of Thoracic Oncology • Volume 2, Number 1, January 2007 91
tively long response to chemotherapy is still achievable in
this situation. It is also tempting to speculate what was the
biological background of acquired chemosensitivity. A
significant proportion of patients with secondary resistance
to EGFR TKIs harbor exon 20 T790M point mutations,
and several irreversible EGFR TKIs (HKI-272, EKB-569,
and CI-1033) are currently being evaluated in preclinical and
clinical studies in correlation with these mutations.2 The
outcomes of chemotherapy in patients with secondary
EGFR exon 20 point mutations are not described. Other
molecular events of acquired resistance to EGFR-targeted
therapies are less well understood but may include activa-
tion of ras/raf/MAPK/ERK pathway and/or cyclin D1,
leading to the redistribution in the cell cycle and possibly
affecting chemosensitivity.3
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FIGURE 1. Microscopic and mo-
lecular characteristics of the primary
tumor. Nonmucinous bronchioal-
veolar carcinoma (A) (x200) with
strong epidermal growth factor re-
ceptor (EGFR) protein expression
(B) (DAKO Pharm Dx staining kit,
x200), EGFR gene amplification (C )
(hybridization with the LSI EGFR
SpectrumOrange/CEP Spec-
trumGreen Probe, Vysis, Abbott
Molecular), high HER2 gene copy
number (D) (hybridization with the
PathVysion HER-2 DNA Probe Kit,
Vysis, Abbott Molecular) and EGFR
exon 19 E746_A750 deletion (E )
(sequencing analyzed in Genetic
Analyzer ABI PRISM 310).
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